Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.50 |
| ▸ | NOS3 | P29474 | 7/20 | 0.48 |
| ▸ | HTR5A | P47898 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13763134 | 0.76 | HTR5A (0.40) | NOS2NOS3HTR5AHTR1AHTR1D | |
| SCHEMBL31074927 | 0.76 | NOS2 (0.42) | NOS2NOS3HTR2A | |
| Ammonia Solution, Strong SCHEMBL29260817 | 0.72 | HTR5A (0.38) | NOS2NOS3HTR5AHTR1AHTR1D | |
| SCHEMBL2087776 | 0.71 | NOS2 (0.49) | NOS2NOS3 | |
| SCHEMBL19457510 | 0.69 | HTR5A (0.36) | NOS2NOS3HTR5AGPR3 | |
| SCHEMBL18497885 | 0.69 | EDNRB (0.38) | HTR5A | |
| SCHEMBL8060964 | 0.65 | NOS3 (1.00) | NOS2NOS3 | |
| Hydrochloric Acid SCHEMBL8382003 | 0.65 | NOS2 (0.96) | NOS2NOS3HTR5A | |
| SCHEMBL353865 | 0.63 | HTR2A (0.52) | HTR1AHTR7GPR3HTR2A | |
| SCHEMBL11411069 | 0.63 | POLB (0.40) | NOS2NOS3HTR2CNOS1GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059992-A1 | New Compounds | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | claimed |
| EP-2035378-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | claimed |
| US-20080171771-A1 | New Compounds 391 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | claimed |
| WO-2007149033-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | claimed |
| US-20110059992-A1 | New Compounds | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-7855213-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-12-21 | — | — | US | disclosed |
| EP-2035378-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080171771-A1 | New Compounds 391 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2007149033-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059992-A1 | New Compounds | MAPT, PSEN2, PSEN1 | NOS2 834/4885NOS3 854/4885HTR5A 1111/4885 |
| US-20080171771-A1 | New Compounds 391 | PSEN2, PSEN1, MAPT | NOS2 1811/4885NOS3 1601/4885HTR5A 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.